IMC-3G3

· Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for IMC-3G3, covering 2011-06-28 to 2017-03-29. Get the full timeline:

Most recent: Clinical Trial Update: Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme [Phase 2]

See pricing